Gingkoom, 40 mg capsules 30 pcs

Pharmacotherapeutic group Angioprotective agent of plant origin
TATX code: N06DX02

Pharmacological properties

Pharmacodynamics

Increases the body’s resistance to hypoxia, especially brain tissue. Inhibits development of traumatic or toxic cerebral edema, improves cerebral and peripheral blood circulation, improves blood rheology (prevents thrombosis).
It has a dose-dependent regulating effect on the vascular wall, dilates small arteries, increases venous tone. Prevents the formation of free radicals and lipid peroxidation of cell membranes. Normalizes the release, re-uptake and catabolism of neurotransmitters (norepinephrine, dopamine, acetylcholine) and their ability to combine with receptors. It improves metabolism in organs and tissues, promotes macroergic accumulation in cells, increased utilization of oxygen and glucose, normalization of mediator processes in the central nervous system.

Pharmacokinetics

absorption
. After oral administration, the bioavailability of the terpenlactones (ginkgolide A, ginkgolide B and bilobalide) is 80% for ginkgolide A, 88% for ginkgolide B and 79% for bilobalide.

Distribution
Peak plasma concentrations were 16-22 ng/mL for ginkgolide A, 8-10 ng/mL for ginkgolide B, and 27-54 ng/mL for bilobalide after oral tablets. Binding to plasma proteins is 43% for ginkgolide A, 47% for ginkgolide B and
67% for bilobalide.

Evolution
Half-life is 3.9 hours for ginkgolide A, 4-6 hours for ginkgolide B and 2-3 hours for bilobalide.